Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $119K fell 14.4% year over year, ahead of the -18.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 8.5% from the prior quarter. Over 3 fiscal years it compounded at -38.4% a year.
Context
- Depreciation & amortization amounted to 1.3% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -14.4% holds above the trailing-twelve-month pace of -18.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 559K USD
- Year-over-year change
- -22.1%
- 4-year CAGR
- -34.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 559K | -22.1% |
| FY2024 | 2024-12-31 | 718K | -46.6% |
| FY2023 | 2023-12-31 | 1.35M | -43.7% |
| FY2022 | 2022-12-31 | 2.39M | -19.5% |
| FY2021 | 2021-12-31 | 2.96M | — |
Depreciation & Amortization vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 depreciation & amortization of $528K is the lowest of the 10 companies compared; the peer median is $13.46M.
- Its year-over-year change of -18.8% is the 9th highest of 10, against a peer median of +16.5%.
- Depreciation & amortization amounts to 1.1% of revenue for AQST, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $338.79M | +78.0% | +17.6% | 42.5% | |
| LTM Jun 2026 | $101.71M | +26.1% | +2.3% | 12.2% | |
| LTM Sep 2026 | $80.71M | +167.6% | -29.6% | 4.6% | |
| LTM Mar 2026 | $62.85M | +7.5% | +30.7% | 8.7% | |
| LTM Mar 2026 | $13.46M | +95.4% | +63.4% | 6.2% | |
| LTM Mar 2026 | $12.61M | +0.4% | -1.4% | 4.0% | |
| LTM Mar 2026 | $4.96M | -16.3% | -0.3% | 11.8% | |
| LTM Mar 2026 | $4.39M | +16.5% | -0.1% | 6.8% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Mar 2026 | $528K | -18.8% | -38.4% | 1.1% | |
| Peer median (excluding AQST) | $13.46M | +16.5% | +2.3% | 6.8% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | 14.99M | 19.39M | 20.83M | 17.87M | 17.15M |
| Gross Profit | 35.84M | 28.29M | 29.75M | 39.69M | 27.39M |
| Gross Margin | 70.5% | 59.3% | 58.8% | 69.0% | 61.5% |
| Research & Development | 17.05M | 17.48M | 13.1M | 20.28M | 17.19M |
| Selling, General & Admin | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| Operating Expenses | 70.52M | 70.36M | 44.85M | 70.46M | 97.04M |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 559K |
| EBITDA | (45.11M) | (39.58M) | 1.18M | (26.62M) | (66.13M) |
| EBITDA Margin | -88.8% | -83.0% | 2.3% | -46.2% | -148.4% |
| Operating Income | (34.68M) | (42.07M) | (15.1M) | (30.77M) | (69.65M) |
| Operating Margin | -68.2% | -88.2% | -29.9% | -53.5% | -156.4% |
| Interest Income | 423K | 99K | 16.32M | 3.44M | 0 |
| Interest Expense | 22.46M | 12.44M | 7.46M | 16.82M | 17.1M |
| Other Income / Expenses | (35.86M) | (12.34M) | 7.48M | (13.38M) | (14.13M) |
| Income Before Tax | (70.54M) | (54.41M) | (7.63M) | (44.15M) | (83.78M) |
| Pre-Tax Margin | -138.8% | -114.1% | -15.1% | -76.7% | -188.1% |
| Income Tax Expense | 0 | 0 | 245K | (14K) | 0 |
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Net Margin | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
| EPS (Basic) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| EPS (Diluted) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| Weighted Avg Shares | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Weighted Avg Shares (Diluted) | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.